BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26

• Press Releases

  Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

  October 8, 2026

   · 

  8 min read
• Press Releases

  Vektor Medical Announces AMA CPT Editorial Panel Approval of New Category I CPT Code for Non-Invasive Ventricular Arrhythmia Localization

  October 8, 2026

   · 

  4 min read
• Press Releases

  Endeavor BioMedicines’ WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients With IPF

  October 8, 2026

   · 

  6 min read
• Press Releases

  XCath Robotics’ Iris System Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) for Remote Robotic-Assisted Mechanical Thrombectomy in Acute Ischemic Stroke

  October 8, 2026

   · 

  4 min read
• 

  Funding

  Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset

  Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.

  October 8, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers

  For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.

  October 8, 2026

   · 

  4 min read

   · 

  Annalee Armstrong
• Press Releases

  Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

  October 8, 2026

   · 

  8 min read
• Press Releases

  Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

  October 8, 2026

   · 

  6 min read
• Press Releases

  CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

  October 8, 2026

   · 

  3 min read
• Press Releases

  CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

  October 8, 2026

   · 

  4 min read